Who
Syed Ali-aamir Rizvi
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Rocket Pharmaceuticals; Chief Medical Officer, Poseida Therapeutics; Chief Medical Officer, Caribou Biosciences.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $36K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 25 Jan 2022
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —61,963 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,037 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,037 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —61,963 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —383,854 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —283,018 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —62,893 at $0.00 | filing |
| 8 Jan 2025filed 8 Jan 2025 | Poseida Therapeuticsoption or derivative | SEC FORM 4 Code D | —250,000 at $0.00 | filing |
| 8 Jan 2025filed 8 Jan 2025 | Poseida Therapeutics | SEC FORM 4 Code U | —185,000 | filing |
| 1 Apr 2024filed 3 Apr 2024 | Poseida Therapeuticsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | Poseida Therapeutics | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 19 Jan 2023filed 20 Jan 2023 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $36K5,627 at $6.31 | filing |
| 25 Jan 2022filed 25 Jan 2022 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —161,250 at $0.00 | filing |
| 25 Jan 2022filed 25 Jan 2022 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $5.50CRBU · dailypolitical.com · 19 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)CRBU · tickerreport.com · 14 Oct 2026Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 TrialCRBU · medicaldaily.com · 10 Oct 2026
0 headlines in the last 90 days name Syed Ali-aamir Rizvi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.